Acelrx Pharmaceuticals Inc (ACRX) Files Form 4 Insider Buying : Howard B Rosen Buys 10,206 Shares

Acelrx Pharmaceuticals Inc (ACRX): Howard B Rosen , CEO of Acelrx Pharmaceuticals Inc purchased 10,206 shares on May 13, 2016. The Insider buying transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.26 per share for a total value of $33,271.56 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 12, 2016, Mark G Edwards (director) purchased 15,000 shares at $3.15 per share price.On May 20, 2015, Howard B Rosen (CEO) purchased 35,400 shares at $0.00 per share price.Also, On Apr 23, 2015, Richard Afable (director) purchased 1,000 shares at $10.30 per share price.

AcelRx Pharmaceuticals Inc: On Friday, May 13, 2016 heightened volatility was witnessed in AcelRx Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $3.08 and hit $3.28 on the upside , eventually ending the session at $3.21, with a gain of 5.25% or 0.16 points. The heightened volatility saw the trading volume jump to 2,25,495 shares. The 52-week high of the share price is $5.88 and the company has a market cap of $145 M . The 52-week low of the share price is at $2.59.

AcelRx Pharmaceuticals Inc Money Flow Index Chart

AcelRx Pharmaceuticals Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company’s lead product candidate Zalviso is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02) a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03) is a single fixed-dose combination drug product designed to provide mild sedation anxiety reduction and pain relief and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.

Leave a Reply

AcelRx Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AcelRx Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.